LuMind IDSC signs on to NTG statement re: Aduhelm
“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…
Rigsby RigsbyOctober 27, 2021
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group…
FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003
Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA…
Rigsby RigsbyOctober 27, 2021
Progress in Alzheimer’s Disease Builds Renewed Interest in Research
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen…
Rigsby RigsbyOctober 27, 2021
Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer’s Disease
The NTG brought together a national panel of expert researchers and practitioners in the field…
Rigsby RigsbyOctober 20, 2021
A New Perspective on The Aduhelm Controversy
In June, the FDA granted “accelerated approval” to Biogen’s Aduhelm drug. This is the first…
Rigsby RigsbyOctober 15, 2021
Alzheimer’s Disease Video Journal Segment 8
The video below is segment 8a of our Alzheimer's Disease Video Journal, which consists of…
Rigsby RigsbyOctober 5, 2021
Aging and Alzheimer’s Disease Webinar
The video below is a recording of a webinar presented by Brian Chicoine, MD and…
Capetivate capetivateSeptember 29, 2021
Aging and Alzheimer’s Disease
This document contains the slides from a webinar on aging and Alzheimer's disease in presented…
Capetivate capetivateSeptember 29, 2021
Alzheimer’s Disease Video Journal Segment 7
The video below is the seventh segment of our Alzheimer's Disease Video Journal, which consists…
Capetivate capetivateSeptember 13, 2021